Consumers across the United States may qualify for compensation following multistate settlements resolving allegations of generic drug price-fixing between 2009 and 2019. In February 2026, state attorneys general announced new settlement agreements with pharmaceutical companies accused of participating in anticompetitive conduct affecting prescription drug prices.
A coalition of 48 states and territories, including Idaho, participated in the litigation. The most recent settlements involve Lannett Company Inc. and Bausch Health US LLC, along with related entities. Idaho joined other states in securing approximately $17.85 million in combined settlements from the companies in this phase of the case.
While Idaho is highlighted in this announcement, the settlement framework is multistate in nature, and eligibility and compensation may vary depending on a consumer’s state of residence and participation in the agreement.
State officials alleged that the companies engaged in coordinated efforts to increase prices and reduce competition in the generic drug market. The companies agreed to financial settlements while denying wrongdoing. The agreements also require compliance measures and cooperation with ongoing investigations.
The lawsuits allege that certain generic drug manufacturers engaged in widespread, long-running conspiracies to artificially inflate prices and allocate markets for specific medications. The conduct allegedly occurred between May 1, 2009, and December 31, 2019.
Generic drugs contain the same active ingredients as their brand-name counterparts and must meet federal standards for safety, strength, quality, and performance. Because generic drugs represent a large proportion of prescriptions dispensed in the United States, pricing practices in this market can affect millions of patients and public healthcare programs.
The litigation does not question the clinical effectiveness or safety of the medications involved. Instead, it focuses on alleged violations of state and federal antitrust laws that prohibit price-fixing and collusion.
States announced the latest agreements in early February 2026. Idaho joined the settlement along with dozens of other states as part of coordinated multistate complaints filed over several years.
These agreements form part of broader litigation targeting multiple pharmaceutical manufacturers. Although the $17.85 million figure reflects only one phase of the case, it represents a portion of a much larger effort by states to address alleged anticompetitive practices across the generic drug industry.
Consumers, businesses, and third-party payers who purchased certain generic prescription drugs during the covered period may be eligible to submit claims for compensation.
Eligibility depends on whether the drug purchased appears on the official settlement list and whether the purchase occurred within participating jurisdictions during the specified timeframe.
State officials have directed eligible individuals to official settlement websites for details about the claims process, documentation requirements, and filing deadlines.
Residents who wish to check whether they qualify for compensation can contact the claims administrator by calling 1-866-290-0182, sending an email to info@AGGenericDrugs.com, or visiting the official website at www.AGGenericDrugs.com.
(Rh/SS/MSM)
